SAN MATEO – October 29, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech, has launched with Unravel Biosciences as its founding development partner to pursue treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Unravel co-founder and CEO Richard Novak, PhD, has joined Astrosalva's board of directors.